| Southwestern Eye Center | |
| 1121 S Gilbert Rd, Ste 103, Mesa, Arizona 85204 | |
| (480) 854-3310 |
| Name | Southwestern Eye Center |
|---|---|
| Organization Name | Southwestern Eye Center, Ltd |
| Location | 1121 S Gilbert Rd, Ste 103, Mesa, Arizona 85204 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (480) 854-3310 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Small non-coding RNA molecules, called microRNAs (miRNAs), found and measured in the blood plasma of asymptomatic pregnant women may predict development of preeclampsia, a condition characterized by high blood pressure and abnormal kidney function that affects roughly 5 to 8 percent of all pregnancies.
A team of researchers from the Peninsula College of Medicine and Dentistry are part of a wider group of researchers from leading institutions that will implement a -4.7m Policy Research Unit dedicated to achieving early cancer screening and diagnosis. The funding is provided over five years by the Department of Health and will be led by Queen Mary, University of London.
GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.
Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.
GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study.
› Verified 3 days ago
| NPI Number | 1063980662 |
| Organization Name | SOUTHWESTERN EYE CENTER LTD |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1121 S Gilbert Rd Ste 103, Mesa, AZ 85204 |
| Phone Number | 480-854-3310 |
News Archive
Small non-coding RNA molecules, called microRNAs (miRNAs), found and measured in the blood plasma of asymptomatic pregnant women may predict development of preeclampsia, a condition characterized by high blood pressure and abnormal kidney function that affects roughly 5 to 8 percent of all pregnancies.
A team of researchers from the Peninsula College of Medicine and Dentistry are part of a wider group of researchers from leading institutions that will implement a -4.7m Policy Research Unit dedicated to achieving early cancer screening and diagnosis. The funding is provided over five years by the Department of Health and will be led by Queen Mary, University of London.
GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.
Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.
GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study.
› Verified 3 days ago
News Archive
Small non-coding RNA molecules, called microRNAs (miRNAs), found and measured in the blood plasma of asymptomatic pregnant women may predict development of preeclampsia, a condition characterized by high blood pressure and abnormal kidney function that affects roughly 5 to 8 percent of all pregnancies.
A team of researchers from the Peninsula College of Medicine and Dentistry are part of a wider group of researchers from leading institutions that will implement a -4.7m Policy Research Unit dedicated to achieving early cancer screening and diagnosis. The funding is provided over five years by the Department of Health and will be led by Queen Mary, University of London.
GTx, Inc. today announced that in a Phase II, open label, pharmacokinetic-pharmacodynamic clinical trial, GTx-758, an oral selective estrogen receptor alpha agonist being developed to treat advanced prostate cancer, suppressed serum total testosterone to castrate levels, increased serum SHBG (sex hormone binding globulin), and markedly reduced serum free testosterone in healthy male volunteers.
Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.
GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study.
› Verified 3 days ago
Osco Drug #0980 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1951 W Baseline Rd, Mesa, Arizona 85202 Phone: (480) 456-4850 | |
Osco Drug #1002 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 9243 E Baseline Rd, Mesa, Arizona 85209 Phone: (480) 986-4660 | |
Osco Drug #1948 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 441 N Val Vista Dr, Mesa, Arizona 85213 Phone: (480) 830-5185 | |
Osco Drug #3989 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2727 N Power Rd, Mesa, Arizona 85215 Phone: (480) 396-3838 | |
Osco Pharmacy # 958 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 325 S Power Rd, Mesa, Arizona 85206 Phone: (480) 924-8928 |